With the growing availability of next-generation sequencing and multigene panel testing, health care professionals and women diagnosed with breast cancer increasingly seek to incorporate this information into shared clinical decision-making.14,15,16 We examined development of ER-positive and ER-negative tumor subtype–specific CBC for women carrying deleterious variants in moderate to high-risk breast cancer susceptibility genes. This evidence concerns the gene ESR1 and neoplasm.